Vanguard Group Inc. lifted its holdings in shares of Evolus Inc (NASDAQ:EOLS) by 87.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 406,549 shares of the company’s stock after purchasing an additional 189,277 shares during the quarter. Vanguard Group Inc. owned 1.49% of Evolus worth $7,570,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. TIAA CREF Investment Management LLC raised its holdings in shares of Evolus by 51.2% during the third quarter. TIAA CREF Investment Management LLC now owns 12,259 shares of the company’s stock valued at $228,000 after acquiring an additional 4,151 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Evolus by 58.8% during the third quarter. Teachers Advisors LLC now owns 13,720 shares of the company’s stock valued at $255,000 after acquiring an additional 5,081 shares in the last quarter. Luminus Management LLC bought a new position in shares of Evolus during the third quarter valued at approximately $3,423,000. Point72 Asset Management L.P. bought a new position in shares of Evolus during the third quarter valued at approximately $14,113,000. Finally, PointState Capital LP bought a new position in Evolus in the third quarter worth $12,289,000. 27.04% of the stock is owned by institutional investors.
In other news, Director Vikram Malik acquired 7,800 shares of the firm’s stock in a transaction on Monday, December 17th. The stock was acquired at an average price of $13.04 per share, for a total transaction of $101,712.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David N. Gill acquired 3,000 shares of the firm’s stock in a transaction on Friday, December 14th. The stock was purchased at an average price of $12.77 per share, with a total value of $38,310.00. The disclosure for this purchase can be found here.
A number of research firms have issued reports on EOLS. HC Wainwright began coverage on Evolus in a report on Thursday, February 14th. They issued a “buy” rating and a $37.00 price objective for the company. Zacks Investment Research downgraded Evolus from a “hold” rating to a “sell” rating in a report on Tuesday, February 5th. Finally, Stifel Nicolaus began coverage on Evolus in a report on Monday, January 28th. They issued a “buy” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Evolus currently has an average rating of “Buy” and a consensus target price of $30.86.
EOLS opened at $26.44 on Friday. The firm has a market capitalization of $741.20 million and a price-to-earnings ratio of -97.93. Evolus Inc has a 12-month low of $6.75 and a 12-month high of $39.50.
COPYRIGHT VIOLATION WARNING: “Evolus Inc (EOLS) Stake Lifted by Vanguard Group Inc.” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://transcriptdaily.com/2019/03/01/evolus-inc-eols-stake-lifted-by-vanguard-group-inc.html.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Featured Article: When is a capital gain realized?
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus Inc (NASDAQ:EOLS).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.